CRANBURY, N.J., Oct. 22, 2021 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a specialized
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin peptide
receptor system, announced that its pre-clinical diabetic
retinopathy poster demonstrating the positive effects of
melanocortin agonists for retinal inflammation was awarded a Top 10
Posters designation at the American Society of Retina
Specialists (ASRS) 2021 Annual Meeting.
"We appreciate this acknowledgement and recognition by the
medical and scientific community of the extraordinary potential of
melanocortin agonists to treat inflammatory diseases," said
Carl Spana, PhD, CEO and President
of Palatin. "Our research team includes experts in
melanocortin drug development that consistently produce robust and
comprehensive data demonstrating the potential of Palatin's
melanocortin agonists in treating inflammatory conditions of the
eye, gut, kidney and other indications."
The presentation highlighting the positive pre-clinical
protective effects of melanocortin 1 receptor agonists PL8331 and
PL9654 in mouse models of retinopathy, and the possible utility of
melanocortins in the treatment of diabetic retinopathy and
choroidal neovascularization, was made at the ASRS 2021 Annual
Meeting, held October 8-12, 2021.
"We are honored to have our poster recognized by ASRS as a Top
10 poster," said John Dodd, PhD,
Senior Vice President of Preclinical Research at Palatin. "It
speaks to the interest and enthusiasm in the scientific community
about the potential of the melanocortin mechanism to treat
inflammatory conditions. We are excited to share this retina and
other inflammatory disease model data where we see melanocortin
agonists work so well."
A link to the ASRS conference website and short video
presentation about the poster by John
Dodd, PhD, can be found here: 2021 Top 10 Poster Award
Winners - The American Society of Retina Specialists (asrs.org)
About Melanocortins and Inflammation
The melanocortin
receptor ("MCr") system has effects on food intake, metabolism,
sexual function, inflammation, and immune system responses. There
are five melanocortin receptors, MC1r through MC5r. Modulation of
these receptors, through receptor-specific agonists, which activate
receptor function, or receptor-specific antagonists, which block
receptor function, can have significant pharmacological
effects.
Many tissues and immune cells located in various organs such as
the eye. gut, and kidney express melanocortin receptors, providing
the opportunity to directly activate natural pathways to resolve
disease inflammation.
About Palatin
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin and natriuretic peptide
receptor systems, with targeted, receptor-specific product
candidates for the treatment of diseases with significant unmet
medical need and commercial potential. Palatin's strategy is to
develop products and then form marketing collaborations with
industry leaders to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin's
website at www.palatin.com.
Forward-looking Statements
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin, such as statements about clinical
trial plans and potential results for clinical or pre-clinical
programs, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Palatin intends
that such forward-looking statements be subject to the safe harbors
created thereby. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-awarded-top-10-poster-designation-at-the-american-society-of-retina-specialists-asrs-2021-annual-meeting-301406509.html
SOURCE Palatin Technologies, Inc.